Thursday, March 26, 2015 1:54:03 AM
Using S&P Capital IQ's financial database software I was able to get a few things out for you guys. See below the thorough analysis.
Based on the closest industry comparables the software along with some of my own inputs calculated trading multiples, enterprise values, market cap, etc...
You will find below the range of valuations it calculated based on current info (note that the average of Low, Mean, Median, High ranges where all calculated based on industry info - I have included further below only the "Mean" Targets of each valuation method):
Mean Equity Value(MKT CAP.$MM) Across All Multiples -- Price Per Share
High 101.30 ______________________________________ $2.74
Low 31.71 _______________________________________ $0.86
Mean 56.57 ______________________________________ $1.53
Median 46.76 ______________________________________ $1.27
For your own info the trading valuations used are below (Mean Target Value in Brackets):
LTM TEV/Total Revenues (1.50$ based on avg. industry revenue multiplier of 5.1 times)
LTM TEV/EBITDA (1.30$ based on avg. EBITDA multiple of 15.9)
LTM TEV/EBIT (1.60$ based on EBIT multiple of 20.20)
LTM P/Diluted EPS ($2.44 based on a multiple of 36.3 and 0.07 eps - Yes the P/E in the card industry is exceptionally high - for your info Visa valued at a P/e of 47, planet payment 36, etc.. we have much room to go)
LTM P/TangBV (0.81 with 15.2 multiple).
As can be seen, this is just the start for 3Pea. The valuations above are simply as of "right now" meaning any further growth will simply propel the implied value even higher!
Best of Luck,
E.
Recent PAYS News
- Paysign to Host First Quarter 2024 Earnings Call • Business Wire • 04/09/2024 08:30:00 PM
- Paysign, Inc. to Sponsor the 2024 International Plasma Protein Congress April 16-17 • Business Wire • 03/14/2024 08:30:00 PM
- Paysign, Inc. Reinforces Payment Processing Acumen With New Executive Hire • Business Wire • 03/13/2024 08:30:00 PM
- Paysign, Inc. to Sponsor the 2024 Gene Therapy for Rare Disorders Conference March 26-29 • Business Wire • 03/12/2024 08:30:00 PM
- Paysign Inc. to Sponsor the 2024 ACCESS USA Conference March 19-21 • Business Wire • 03/11/2024 08:30:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/07/2024 11:22:09 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/07/2024 11:14:01 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/05/2024 01:07:20 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/04/2024 12:51:22 PM
- Paysign to Host Fourth Quarter and Full Year 2023 Earnings Call • Business Wire • 02/27/2024 09:30:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/21/2024 11:01:31 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/21/2024 10:55:56 PM
- Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] • Edgar (US Regulatory) • 02/12/2024 05:36:58 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/06/2024 11:50:15 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/06/2024 11:44:04 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/31/2024 11:57:43 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/31/2024 11:49:18 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/26/2024 12:50:43 AM
- Form 3 - Initial statement of beneficial ownership of securities • Edgar (US Regulatory) • 01/26/2024 12:26:53 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/26/2024 12:03:20 AM
- Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] • Edgar (US Regulatory) • 01/24/2024 09:05:27 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/08/2023 12:56:05 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/07/2023 09:00:10 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 11/02/2023 09:44:16 PM
NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • NNVC • May 2, 2024 10:07 AM
ILUS Files Form 10-K and Provides Shareholder Update • ILUS • May 2, 2024 8:52 AM
Avant Technologies Names New CEO Following Acquisition of Healthcare Technology and Data Integration Firm • AVAI • May 2, 2024 8:00 AM
Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM
Cannabix Technologies to Deliver Breath Logix Alcohol Screening Device to Australia • BLO • Apr 30, 2024 8:53 AM
Hydromer, Inc. Reports Preliminary Unaudited Financial Results for First Quarter 2024 • HYDI • Apr 29, 2024 9:10 AM